ArticleNature2020
Pervasive chromosomal instability and karyotype order in tumour evolution.
Open access · goldAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 235 papers.
0numbers the graph read from it
0cells of the map it votes in
235citing papers in PubMed
22.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
235 citing papers in PubMed, 396 citations in OpenAlex.
- Trial
- Accumulation of copy number alterations and clinical progression across advanced prostate cancer.Genome medicine · 2022Trial
- Second primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management.Human vaccines & immunotherapeutics · 2026Review
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- Chromosomal instability in cancer: sources, consequences and new therapeutic opportunities.Signal transduction and targeted therapy · 2026Review
- Article
- Gene mutant dosage is associated with prognosis and metastatic tropism in 60,000 clinical cancer samples.Nature genetics · 2026Article
- Charting intratumor heterogeneity from bench to bedside.Nature cancer · 2026Review
- BAP1 deficiency-induced SKA3 promotes clear cell renal cell carcinoma malignant progression by regulating chromosomal instability.Cell death & disease · 2026Article
- Tumor heterogeneity: development, mechanisms, and therapeutic implications.Signal transduction and targeted therapy · 2026Review
- Dynamic ecosystems of tumor drug resistance mechanisms: from molecular heterogeneity to systemic interventions.Apoptosis : an international journal on programmed cell death · 2026Review
- Aneuploidy confers environmentally robust higher evolvability than euploidy in a synthetic allotetraploid wheat.Science advances · 2026Article
- Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Impact of Chromosomal Instability and Aneuploidy in Cancer Development.Annual review of cancer biology · 2026Article
- A comprehensive foundation model for generalizable cytogenetics in precision oncology with CHROMA.NPJ precision oncology · 2026Article
- Is cancer the result of uncontrolled cellular growth? a glance into the tumorigenic process.Cancer cell international · 2026Review
- Gene duplication is associated with gene diversification and potential neofunctionalization in lung cancer evolution.Genome research · 2026Article
- Observational
- Negative Selection Maintains Grossly Altered but Broadly Stable Karyotypes in Metastatic Colorectal Cancer.Cancer discovery · 2026Article
175 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 12 countries.
Thomas B K Watkins *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Emilia L Lim *Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Marina PetkovicBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany.ORCID http://orcid.org/0000-0003-2875-216X
Sergi ElizaldeDepartment of Mathematics, Dartmouth College, Hanover, NH, USA.ORCID http://orcid.org/0000-0003-4116-2455
Nicolai J BirkbakCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-1613-9587
Gareth A WilsonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
David A MooreCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Eva GrönroosCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-8303-5409
Andrew RowanCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Sally M DewhurstLaboratory for Cell Biology and Genetics, Rockefeller University, New York, NY, USA.
Jonas DemeulemeesterCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-2660-2478
Stefan C DentroCancer Genomics Laboratory, The Francis Crick Institute, London, UK.
Stuart HorswellDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2787-1933
Lewis AuRenal and Skin Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
Kerstin HaaseCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-0944-5618
Mickael EscuderoDepartment of Bioinformatics and Biostatistics, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1336-815X
Rachel RosenthalCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Maise Al BakirCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Hang XuStanford Cancer Institute, Stanford, CA, USA.
Kevin LitchfieldCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.
Wei Ting LuCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0002-1405-4806
Thanos P MourikisCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Michelle DietzenCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Lavinia SpainRenal and Skin Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
George D CresswellBioinformatics and Computational Biology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-3303-068X
Dhruva BiswasCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-9141-5188
Philippe LamyDepartment of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark.
Iver NordentoftDepartment of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark.
Katja HarbstDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-8225-1510
Francesc Castro-GinerDepartment of Biomedicine, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Basel, Switzerland.ORCID http://orcid.org/0000-0001-6111-0754
Lucy R YatesWellcome Trust Sanger Institute, Hinxton, UK.
Franco CaramiaDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0002-5086-2544
Fanny JaulinINSERM U1279, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-5110-1800
Cécile VicierDepartment of Medical Oncology, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France.
Ian P M TomlinsonEdinburgh Cancer Research Centre, IGMM, University of Edinburgh, Edinburgh, UK.
Priscilla K BrastianosBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA.
Raymond J ChoDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-6090-6603
Boris C BastianDepartment of Dermatology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-1836-6062
Lars DyrskjøtDepartment of Molecular Medicine (MOMA), Aarhus University Hospital, Aarhus, Denmark.ORCID http://orcid.org/0000-0001-7061-9851
Göran B JönssonDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden.
Peter SavasDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-5999-428X
Sherene LoiDivision of Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.ORCID http://orcid.org/0000-0001-6137-9171
Peter J CampbellWellcome Trust Sanger Institute, Hinxton, UK.ORCID http://orcid.org/0000-0002-3921-0510
Fabrice AndreINSERM U981, PRISM Institute, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0001-5795-8357
Nicholas M LuscombeBioinformatics and Computational Biology Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0001-5293-4778
Neeltje SteeghsDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Vivianne C G Tjan-HeijnenDepartment of Medical Oncology, School of GROW, Maastricht University Medical Center, Maastricht, The Netherlands.
Zoltan SzallasiDanish Cancer Society Research Center, Copenhagen, Denmark.
Samra TurajlicRenal and Skin Units, The Royal Marsden Hospital NHS Foundation Trust, London, UK.ORCID http://orcid.org/0000-0001-8846-136X
Mariam Jamal-HanjaniCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Peter Van LooCancer Genomics Laboratory, The Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0292-1949
Samuel F BakhoumHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roland F SchwarzBerlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine, Berlin, Germany. roland.schwarz@mdc-berlin.de.ORCID http://orcid.org/0000-0001-9155-4268
Nicholas McGranahanCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. nicholas.mcgranahan.10@ucl.ac.uk.ORCID http://orcid.org/0000-0001-9537-4045
Charles SwantonCancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. charles.swanton@crick.ac.uk.ORCID http://orcid.org/0000-0002-4299-3018
The Francis Crick Institute · GBAarhus University Hospital · DKCancer Research UK · GBRoyal Marsden NHS Foundation Trust · GBThe University of Melbourne · AUInserm · FRLund University · SERoyal London Hospital · GBUniversity of California, San Francisco · USAarhus University · DKAix-Marseille Université · FRBroad Institute · USCancer Prevention Institute of California · USDartmouth College · USEdinburgh Cancer Research · GBGerman Cancer Research Center · DEGuy's and St Thomas' NHS Foundation Trust · GBMaastricht University · NLMax Delbrück Center · DEMemorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMolecular and immunologic evolution of melanomas from pre-neoplastic lesionsR35CA220481 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BASTIAN, BORIS C. · 2017 to 2023
$6.3MProbing cytosolic nucleic acid sensing pathways in cancerR01CA256188 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LAUGHNEY, ASHLEY MARIE · 2021 to 2025
$3.5MThe role of chromosomal instability in tumor evolutionDP5OD026395 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI BAKHOUM, SAMUEL F · 2018 to 2022
$2.2MCancer Research UK 17786Cancer Research UK 18176Cancer Research UK 20466Cancer Research UK 21999Cancer Research UK 24956Cancer Research UK 29911Cancer Research UK 30025Cancer Research UK FC001110European Research CouncilMedical Research Council FC001169Medical Research Council FC001202Medical Research Council MR/L016311/1Medical Research Council MR/P014712/1Medical Research Council MR/P014712/2NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA256188NCI NIH HHS R35 CA220481NIH HHS DP5 OD026395Wellcome TrustWellcome Trust 211179/Z/18/ZWellcome Trust 214584/Z/18/ZWellcome Trust FC001169Wellcome Trust FC001202Wellcome Trust FC010110
Abstract
Chromosomal instability in cancer consists of dynamic changes to the number and structure of chromosomes
Indexed as
Evolution, MolecularKaryotypeChromosomal InstabilityChromosomes, Human, Pair 11Chromosomes, Human, Pair 8Clone CellsCyclin EDNA Copy Number VariationsFemaleHumansLoss of HeterozygosityMaleMutagenesisNeoplasm MetastasisNeoplasmsOncogene ProteinsCCNE1 protein, humanCyclin EOncogene Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.